Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Progressive Corporation Add to portfolio

INX:PGR, Jul 17, 07:28 UTC

Latest INX:PGR News

Filter your feed

Apply Filter

Today


News

Progressive Reports June 2019 Results

PGR

MAYFIELD VILLAGE, OHIO, July 17, 2019 (GLOBE NEWSWIRE) -- The Progressive Corporation (PGR) today reported the following results for June 2019 and the second quarter of 2019:. The Progressive Group of Insurance Companies makes it easy to understand, buy and use auto insurance. Progressive offers choices so consumers can reach us whenever, wherever and however it's most convenient - online at progressive.com, by phone at 1-800-PROGRESSIVE, on a mobile device or in-person with a local agent. Progressive is the third largest auto insurer in the country; a leading seller of motorcycle and commercial auto insurance; and through ASI, one of the top 15 homeowners insurance carriers.

Read Full Details

Topics:
  • Business
  • Financial

Sunday, July 14


News

Drilling into the Technicals & Valuation For American International Group, Inc. (NYSE:AIG)

PGR AIG

Investors might be trying to figure out an investment plan that is right for them. Some may opt to go with a short-term plan, and others may choose to invest in stocks for the long haul. The element of correct timing comes into play when trying to enter or exit a position, which may not be for everyone. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, July 11


News

MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

PGR

The rationale for enrolling this type of progressive MS is the following:. Approximately 15% of MS patients are diagnosed with primary progressive MS (PPMS) at onset and exhibit gradually increasing disability in walking, vision, mental acuity, and other bodily functions without experiencing relapses or remissions. MediciNova has a portfolio of patents which covers the use of MN-166 (ibudilast) to treat various diseases including progressive MS, ALS, and drug addiction. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, we may not successfully complete our Phase 3 clinical trial of MN-166 on a timely basis or at all, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2018 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Tuesday, July 09


News

Why Progressive Stock Is Up 32.5% in the First Half of 2019

PGR

Shares of Progressive(NYSE: PGR) climbed 32.5% in the first half of 2019, according to data provided by S&P Global Market Intelligence. Progressive has been on a roll over the last two years, fueling a sharp rise in the stock price. Progressive turned in another strong quarterly report in early May, with net written premiums up 16% over the prior-year period and an underwriting margin of 11.2%. At the start of 2019, the stock traded for a forward P/E of less than 12, but now trades for 15.7 times this year's earnings estimate, which explains part of the 32.5% advance in the shares so far this year. So what.

Read Full Details

Topics:
  • Business
  • Financial

Thursday, July 04


News

Secondary Progressive Multiple Sclerosis Drug Market 2019 – AB Science SA, Actelion Ltd, Biogen, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation – Industry Reports

PGR

Report analyzes changing trends and competitive analysis which becomes essential to monitor performance and make critical decisions for growth and development. In addition, the report evaluates key market aspects, comprising capacity utilization rate, revenue, price, capacity, growth rate, gross, production, consumption, supply, export, market share, cost, import, gross margin, demand, and much more. Secondary Progressive Multiple Sclerosis Drug report provides detailed information that is changing which helps to keep you ahead from other competitors. Additionally, major events and innovations in Secondary Progressive Multiple Sclerosis Drug market report • Study of business strategies of prominent players • Study of growth plot of Secondary Progressive Multiple Sclerosis Drug market during the forecast period • Pin-point analysis of drivers and restraints for the market • Technological advancements and changing trends striking Secondary Progressive Multiple Sclerosis Drug market.

Read Full Details

Topics:
  • Business
  • Financial

Friday, June 21


News

Global Progressive Scan Color Camera Market 2019 – Axis Communications, Jai, Hitachi Kokusai Electric America – Industry News Updates

PGR

The Report gives you competition analysis of top manufacturer with sales volume, price, revenue (Million USD) and market share, the top players including Axis Communications, Jai, Hitachi Kokusai Electric America, Edmund Optics, Takex-system, Edmund Optics, Euresys, BitFlow. Global Progressive Scan Color Camera market size expected to reach xx Million USD by 2024, from xx Million USD in 2017, at a CAGR of xx% during the forecast period (2018-2024). In this study report, 2017 has been considered as the base year, 2018 as the Estimated Year, (2013-2017) as the History Year and 2018 to 2024 as the forecast period to estimate the market size for Progressive Scan Color Camera. 2) To strategically analyze each submarket with respect to individual growth trend and their contribution to the Global Progressive Scan Color Camera Market 3) To strategically profile the key players and comprehensively analyze their growth strategies.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, June 14


News

'Progressive' coalition poised to lead Brussels regional parliament

PGR FB

Party leaders will announce a majority coalition between the greens, liberals and socialists which will likely lead the Brussels regional parliament throughout the new legislative term. The parliament of the Brussels-Capital Region could be the first regional parliament in the country to announce a ruling majority coalition on Friday, following the elections in May. With the informal discussions concluded, a self-proclaimed “progressive” majority coalition of greens, liberals and socialists appears poised to lead the new legislative term of the regional parliament. With ten seats each, liberals at DéFi tied with the extreme-left labour PTB party, but the latter does not appear to have been included in the informal talks, and a plan to team up with the PS in Wallonia’s regional parliament appears to be on the rocks.

Read Full Details

Topics:
  • Business
  • Politics
  • Science
  • World

Wednesday, June 12


News

Trump's War on Science is Grounds to Impeach - Progressive.org

PGR

A recent study conducted by Australian climate experts has forecasted that rapidly warming global temperatures could cause human civilization to collapse as early as 2050. Since the earliest days of the Trump Administration, we’ve heard how Trump and his allies may have covered up evidence and obstructed investigations into Russiagate and other improprieties. Unsurprisingly, this has led to calls for the President’s impeachment. But there are other, more serious forms of obstruction that haven’t generated anywhere near as much attention, despite potentially catastrophic consequences for the country and the world. And the most dangerous of these has been the Trump administration’s near-constant war on science. A recent report by the Union of Concerned Scientists, “Science under Siege at the Department of the Interior,” documents how the Trump team has set out to obfuscate the findings of scientists through the use of censorship and distortion. And just this month, the State Department blocked a State Department official from testifying to Congress on the “possibly catastrophic” security impacts of climate change, even as an Australian study warned that civilization itself could be under dire threat by 2050. Now there are fresh signs that the Trump Administration intends to actively interfere in research by federal scientists.

Read Full Details

Topics:
  • Business
  • Technology
  • Entertainment
  • Science

Friday, May 31


News

Middleby Corp (MIDD) Stake Increased by Bank of Hawaii – Mayfield Recorder

PGR

Bank of Hawaii grew its stake in shares of Middleby Corp (NASDAQ:MIDD) by 9.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. In other Middleby news, Director John R. Miller III sold 2,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $126.37, for a total value of $252,740.00. Finally, CL King upgraded shares of Middleby from a “buy” rating to a “strong-buy” rating and set a $160.00 target price for the company in a report on Wednesday, April 3rd.

Read Full Details

Topics:
  • Business
  • Financial
News

The Progressive Corporation (PGR) – Don’t lose sight of the bigger picture

PGR

Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to The Progressive Corporation [PGR] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. This is compared to 1 month ago, when its average rating was 2.00. For the quarter ending in Mar-19 The Progressive Corporation [PGR] generated $9.24 billion in sales. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run. The Progressive Corporation [PGR] has a Price to Book Ratio of 3.41, a Price to Cash Flow Ratio of 5.63 and P/E Ratio of 15.93.

Read Full Details

Topics:
  • Business
  • Financial